Literature DB >> 16687931

Genetically engineered human cancer models utilizing mammalian transgene expression.

S DiSean Kendall1, Stacey J Adam, Christopher M Counter.   

Abstract

Cancer models are vital to cancer biology research, and multiple cancer models are currently available that utilize either murine or human cells, each with particular strengths and weaknesses. The ability to transform primary human cells into tumors through the expression of specific transgenes offers many advantages as a cancer model, including genetic malleability and the ability to transform specific cell types. Until recently, the conversion of primary human cells into tumors through transgene expression required the use of viral genetic elements, which unfortunately adds uncertainty regarding which cancer pathways are affected and how they are affected. In recent years multiple reports have described the transformation of primary human cells into tumors using only mammalian transgenes. This review focuses on these five cancer models, comparing the different cell types which were transformed into tumors and which transgenes were expressed, as well as the cancer pathways affected in the disparate models. These genetically-engineered human cancer models offer a valuable tool to complement existing cancer models and further cancer research.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16687931     DOI: 10.4161/cc.5.10.2734

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  13 in total

1.  Aurora-A phosphorylates, activates, and relocalizes the small GTPase RalA.

Authors:  Kian-Huat Lim; Donita C Brady; David F Kashatus; Brooke B Ancrile; Channing J Der; Adrienne D Cox; Christopher M Counter
Journal:  Mol Cell Biol       Date:  2009-11-09       Impact factor: 4.272

2.  Regulation of G1 Cell Cycle Progression: Distinguishing the Restriction Point from a Nutrient-Sensing Cell Growth Checkpoint(s).

Authors:  David A Foster; Paige Yellen; Limei Xu; Mahesh Saqcena
Journal:  Genes Cancer       Date:  2010-11

Review 3.  Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology.

Authors:  Chenguang Wang; Michael P Lisanti; D Joshua Liao
Journal:  Cell Cycle       Date:  2011-01-01       Impact factor: 4.534

4.  Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma.

Authors:  Amir A Jazaeri; Jennifer L Bryant; Hong Park; Hui Li; Neetu Dahiya; Mark H Stoler; James Stuart Ferriss; Anindya Dutta
Journal:  Neoplasia       Date:  2011-10       Impact factor: 5.715

Review 5.  Genetically modified mouse models in cancer studies.

Authors:  Javier Santos; Pablo Fernández-Navarro; María Villa-Morales; Laura González-Sánchez; José Fernández-Piqueras
Journal:  Clin Transl Oncol       Date:  2008-12       Impact factor: 3.405

6.  Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas.

Authors:  Audrey Bouillez; Hasan Rajabi; Sean Pitroda; Caining Jin; Maroof Alam; Akriti Kharbanda; Ashujit Tagde; Kwok-Kin Wong; Donald Kufe
Journal:  Cancer Res       Date:  2016-02-01       Impact factor: 12.701

7.  Are cancer and ageing different sides of the same coin? Conference on Cancer and Ageing.

Authors:  Graham Pawelec; Rafael Solana
Journal:  EMBO Rep       Date:  2008-02-08       Impact factor: 8.807

8.  Histological and molecular evaluation of patient-derived colorectal cancer explants.

Authors:  Joshua M Uronis; Takuya Osada; Shannon McCall; Xiao Yi Yang; Christopher Mantyh; Michael A Morse; H Kim Lyerly; Bryan M Clary; David S Hsu
Journal:  PLoS One       Date:  2012-06-04       Impact factor: 3.240

9.  A Genetic Porcine Model of Cancer.

Authors:  Lawrence B Schook; Tiago V Collares; Wenping Hu; Ying Liang; Fernanda M Rodrigues; Laurie A Rund; Kyle M Schachtschneider; Fabiana K Seixas; Kuldeep Singh; Kevin D Wells; Eric M Walters; Randall S Prather; Christopher M Counter
Journal:  PLoS One       Date:  2015-07-01       Impact factor: 3.240

10.  Ras Post-transcriptionally Enhances a Pre-malignantly Primed EMT to Promote Invasion.

Authors:  Laura S Bisogno; Matthew B Friedersdorf; Jack D Keene
Journal:  iScience       Date:  2018-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.